Handok is responsible for the domestic sales of Korea Abbott's hyperlipidemia treatment Lipidil starting January 1st.

Handok exclusively distributes, sells, and promotes two products, Lipidil Supra and Lipidil NT, in Korea. With the introduction of Lipidil, Handok strengthens its business competitiveness in chronic diseases, adding hyperlipidemia to its existing focus on diabetes and hypertension. Handok has established business leadership in the diabetes field and possesses a comprehensive portfolio of treatments for diabetes, hypertension, and hyperlipidemia, including Megarozet.

Lipidil, containing the active ingredient fenofibrate, is a hyperlipidemia treatment and the most prescribed product in the global and domestic fibrate market (as of November 2024). Lipidil Supra (fenofibrate 160mg) is the original product developed by Abbott. Lipidil NT (fenofibrate 145mg), listed for reimbursement in January 2023, can be taken regardless of meals.

Yoon-Mi Kim, Executive Director of Handok's ETC Division, stated, "Handok is expanding its competitiveness in hypertension and hyperlipidemia based on its successful experience in the diabetes business. The introduction of Lipidil expands our product portfolio in the chronic disease field, which requires a complex treatment approach, and strengthens our position in this area through synergy with existing products."

Handok continues to expand its pipeline in the chronic disease field. The company has secured leadership in the diabetes business with treatments such as Amaryl, Tenelia, Lantus, and the blood glucose meter Barozen. In 2024, Handok launched the hypertension treatment Aprovasc, co-developed with Sanofi, and expanded its competitiveness in the hypertension field by co-marketing Aprovel and CoAprovel.